



IELSG Annual Meeting 2021

Saturday March 13, 2021

From 2:00 pm until 6:00 pm (CET)

Fully virtual event



14:00	Opening Remarks	E. Zucca
14:15 – 15:30	Marginal Zone Lymphoma	
14:15 – 14:35	Novel endpoints for clinical trials: a meta-analysis of the literature and proposal for a study	C. Bommier
14:35 – 14:55	IELSG47 – “MALIBU” – Rituximab and Ibrutinib in MZL – Study update	A. Conconi
14:55 – 15:15	IELSG46 – Integrated molecular and clinical profiling in MZL – Final results	D. Rossi
15:15 – 15:30	IELSG44 – “PIMENTO” – PET imaging in MZL	S. Luminari
15:30	Break	
15:45 – 16:00	TK/T-cell Lymphoma	
15:45 – 16:00	IELSG50 – Pembrolizumab and radiotherapy for previously untreated patients with limited stage NK/T-cell lymphoma. Where are we?	W. Zhao
16:00 – 16:45	Primary Central Nervous System Lymphoma	
16:00 – 16:15	IELSG32 – Long term results and ancillary studies and IELSG45 – “FIORELLA” status	A. Ferreri
16:15 – 16:30	IELSG43 – Where are we?	G. Illerhaus
16:30 – 16:45	Where will we go? – OptiMATE trial	G. Illerhaus
16:45 – 17:15	Primary Mediastinal B-Cell Lymphoma	
16:45 – 17:00	IELSG37 – Statistical analysis plan	E. Zucca
17:00 – 17:15	NEW PROJECT – Understanding radiomics in lymphoma	S. Chauvie
17:15	Break	
17:30	General Assembly and Discussion (IELSG Members Only)	
18:00	Closure Remarks	F. Cavalli

We thank for the kind educational unrestricted support:

Diamond



Gold



BeiGene



Silver



Acerta Pharma



AstraZeneca



GILEAD



MEI
pharma

Bronze

abbvie



BAYER



SANDOZ



Takeda